TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
Haemophilia · 2025
DOI: 10.1111/hae.70070 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Haemophilia, 2025. Verfasst von Kagehiro Amano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Hemorrhage, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Background
Emicizumab is approved for routine prophylaxis, but limited data exist investigating the relationship between bleeds and exercise in people with haemophilia A (PwHA) receiving emicizumab.
Aim
To evaluate the relationship between physical activity and bleeding outcomes in Japanese PwHA receiving emicizumab prophylaxis.
Methods
This prospective, multicentre, observational study was conducted in Japanese PwHA initiating emicizumab between November 2019 and October 2021. Physical activity and bleeding events were reported using an electronic patient‐reported outcomes application, while activity intensity was collected by a wearable activity tracker worn over five 8‐day monitoring periods. Data on safety were recorded by investigators using electronic case report forms. Quality of life data were also collected and will be reported in a separate publication.
Results
Overall, 129 participants enrolled. Median age was 32 years (range 0–73), and 83.7% of participants had severe HA. Overall, 73 participants performed 968 exercise events, with 18.8% and 6.0% of events classified as moderate and high risk, respectively. Two (0.2%) exercise events were associated with bleeding: one basketball (moderate risk) and one fishing (low risk). In total, 137 adverse events (AEs) were reported in 62 participants. No serious AEs were emicizumab‐related. The mean annualised treated bleed rate was 1.9 and 51 (39.5%) participants experienced zero bleeds during the study period (97 weeks).
Conclusion
This study suggests that PwHA receiving emicizumab prophylaxis can participate in a wide range of physical activities with minimal bleeding risk, which supports their access to the health benefits of exercise. Emicizumab remains well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.
- Division of Transfusion Medicine/Hemophilia Treatment Center, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Respiratory Medicine and Hematology, Hyogo Medical University, Hyogo, Japan.
- Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
- Department of Pediatrics, St. Marianna University School of Medicine, Kanagawa, Japan.
- Center for Translational Research/Division of Advanced Medicine Promotion, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
ORCID-Profile: Teruhisa Fujii, Azusa Nagao, Mika Kawano, Keiji Nogami
Förderung
- Chugai Pharmaceutical Co., Ltd
Zitieren
APA
Amano, K., Fujii, T., Sawada, A., Nagao, A., Nagae, C., Nojima, M., Suzuki, N., Kawano, M., Shimura, T., Sugao, Y., Hattori, N., & Nogami, K. (2025). TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab. Haemophilia. https://doi.org/10.1111/hae.70070
Vancouver
Amano K, Fujii T, Sawada A, Nagao A, Nagae C, Nojima M, et al. TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab. Haemophilia. 2025. doi:10.1111/hae.70070
BibTeX
@article{Amano2025,
author = {Amano, Kagehiro and Fujii, Teruhisa and Sawada, Akihiro and Nagao, Azusa and Nagae, Chiai and Nojima, Masanori and Suzuki, Nobuaki and Kawano, Mika and Shimura, Tomomi and Sugao, Yoshimasa and Hattori, Naoto and Nogami, Keiji},
title = {TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70070}
}
EUVIMED